In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Brightgene Bio-medical Technology Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥-5.06.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Brightgene Bio-medical Technology Co's Days Inventory for the
three
months ended in Mar. 2026 was 234.76.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Brightgene Bio-medical Technology Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Brightgene Bio-medical Technology Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.11.
Brightgene Bio-medical Technology Co (SHSE:688166) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Brightgene Bio-medical Technology Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Brightgene Bio-medical Technology Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Brightgene Bio-medical Technology Co Total Inventories Related Terms
Brightgene Bio-medical Technology Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co Total Inventories Chart
Brightgene Bio-medical Technology Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Total Inventories of ¥359 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Brightgene Bio-medical Technology Co and its competitors.
Is Brightgene Bio-medical Technology Co's Total Inventories too high?
Brightgene Bio-medical Technology Co's current Total Inventories is ¥359 Mil. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Total Inventories compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's Total Inventories of ¥359 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current Total Inventories is ¥359 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Total Inventories is ¥359 Mil. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Total Inventories is ¥359 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Total Inventories: ¥359 Mil
GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
